Industrial, Manufacturing & Heavy Industry Market News

Research report explores Europe's diabetic retinopathy market

Research report explores Europe's diabetic retinopathy market

Asia Pacific Hormone Replacement Therapy Market is estimated at USD 2.21 billion in 2016 and is predicted to reach USD 3.23 billion from 2017 - 2021

- Advertising -

Hormone Therapy (HT) remains the most effective option to treat menopausal symptoms. There are many good clinical data to indicate that the use of HT started in early menopause is effective and safe.

The Asia Pacific Hormone Replacement Therapy Market is estimated at USD 2.21 billion in 2016 and is predicted to reach USD 3.23 billion by 2021, growing at a CAGR of 7.92%.

Full report at: www.marketdataforecast.com/market-…erapy-market-961/

Growing awareness on post-menopausal hazards, reimbursement policies, novel formulations, rise in unmet medical needs which require the employment of hormone therapy, benefits like lower risk of fractures are the few factors propelling the prsync.com/market-data-forecast/eu…recast----2102487of Asia Pacific Hormone Replacement therapy market.

- Advertising -

The major factor acting as a hurdle for market prsync.com/market-data-forecast/eu…recast----2102487 in the Asia-Pacific region is the cost of therapy. Normally, the therapy costs around $ 10,000.

This is a pretty high amount considering the economic conditions of people in most of the countries in the Asia-Pacific region. Further, the risk of side effects, such as bloating, mood changes, and nausea, bleeding, breast tenderness or enlargement, headaches, risk of breast cancer, heart disease, and stroke is restraining the prsync.com/market-data-forecast/eu…recast----2102487 of the Asia-Pacific market.

Along with this, women with high susceptibility to coronary diseases are kept away from taking hormone replacement therapy.

The Asia Pacific hormone replacement therapy market is segmented on the basis of hormone type into Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid replacement therapy and others. The estrogen replacement therapy segment dominates the market, representing more than half of the market.

While other therapies are still new in these regions and takes some time to get acquainted. Additionally, on the basis of route of administration the market is classified as oral, parenteral, transdermal and other routes.

The oral route is regarded as one of the safest and most preferred routes of drug administration.

Further, on the basis of geography, the Asia Pacific Hormone Replacement therapy market is analysed under regions namely, India, China, Australia, Japan and South Korea. Japan holds the major prsync.com/market-data-forecast/eu…recast----2102487 of the Asia Pacific Hormone Replacement therapy market while India & China are expected to register high prsync.com/market-data-forecast/eu…recast----2102487 rates during the forecast period.

Report:www.marketdataforecast.com/market-…61/request-sample

Some of the key players operating in the Asia Pacific Hormone Replacement market are F. Hoffmann-La Roche, Novartis, Pfizer, Abbott Laboratories, Mylan Laboratories, Novo Nordisk, Amgen, Merck & Co., Bayer, Eli Lily, Wyeth and Hisamitsu Pharmaceutical Co.

Inc.

 

News From

Market Data Forecast - market research, business intelligence and consultingMarket Data Forecast
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...